ArtifactPublicationStatus: Active

url: Citation 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.

identifier: FEvIR Object Identifier/367878, https://pubmed.ncbi.nlm.nih.gov/38584159, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.60

version: 1.0.0-ballot2

title: 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.

status: Active

date: 2025-09-04 23:28:30+0000

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2024-06-04

lastReviewDate: 2024-06-19

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish

statusDate

activity: PubMed Pubstatus of Received

period: ?? --> 2024-01-19

statusDate

activity: PubMed Pubstatus of Accepted

period: ?? --> 2024-03-01

statusDate

activity: PubMed Pubstatus of Revised

period: ?? --> 2024-02-23

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2024-06-05 02:18:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2024-04-08 00:42:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2024-04-07 23:04:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2024-04-08

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/38584159, https://www.ncbi.nlm.nih.gov/pmc//PMC11150153, https://doi.org/10.1038/s41440-024-01658-y, pii/10.1038/s41440-024-01658-y

relatedIdentifier: https://clinicaltrials.gov/NCT03640312

Titles

-	Type	Text
*	Primary title	Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.

Abstracts

-	Type	Text	Copyright
*	Primary human use	New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with hypertension. QUARTET USA was a randomized (1:1), double-blinded trial conducted in federally qualified health centers among adults with hypertension. Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks. If BP was >130/>80 mm Hg at 6 weeks in either arm, then participants received open label add-on amlodipine 5 mg. The primary outcome was mean change in systolic blood pressure (SBP) at 12 weeks, controlling for baseline BP. Secondary outcomes included mean change in diastolic blood pressure (DBP), and safety included serious adverse events, relevant adverse drug effects, and electrolyte abnormalities. Among 62 participants randomized between August 2019-May 2022 (n = 32 intervention, n = 30 control), mean (SD) age was 52 (11.5) years, 45% were female, 73% identified as Hispanic, and 18% identified as Black. Baseline mean (SD) SBP was 138.1 (11.2) mmHg, and baseline mean (SD) DBP was 84.3 (10.5) mmHg. In a modified intention-to-treat analysis, there was no significant difference in SBP (-4.8 mm Hg [95% CI: -10.8, 1.3, p = 0.123] and a -4.9 mmHg (95% CI: -8.6, -1.3, p = 0.009) greater mean DBP change in the intervention arm compared with the control arm at 12 weeks. Adverse events did not differ significantly between arms. The quadpill had a similar SBP and greater DBP lowering effect compared with candesartan 8 mg. Trial registration number: NCT03640312.	© 2024. The Author(s).

relatesTo

type: Cites

classifier: Journal Article

citation:

NCD-Risk Factor Collaborators. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80. doi: 10.1016/S0140-6736(21)01330-1.

relatesTo

type: Cites

classifier: Journal Article

citation:

Muntner P, Miles MA, Jaeger BC, Hannon Iii L, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971–80. doi: 10.1161/HYPERTENSIONAHA.122.19222.

relatesTo

type: Cites

classifier: Journal Article

citation:

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison-Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;71:e127–e248. doi: 10.1016/j.jacc.2017.11.006.

relatesTo

type: Cites

classifier: Journal Article

citation:

Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104. doi: 10.1093/eurheartj/ehy339.

relatesTo

type: Cites

classifier: Journal Article

citation:

World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. WHO Report: Geneva; 2021.

relatesTo

type: Cites

classifier: Journal Article

citation:

Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–e621. doi: 10.1161/CIR.0000000000001123.

relatesTo

type: Cites

classifier: Journal Article

citation:

Chow CK, Gupta R. Blood pressure control: a challenge to global health systems. Lancet. 2019;394:613–5. doi: 10.1016/S0140-6736(19)31293-0.

relatesTo

type: Cites

classifier: Journal Article

citation:

Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005–2016. Hypertension. 2020;75:973–81. doi: 10.1161/HYPERTENSIONAHA.119.14360.

relatesTo

type: Cites

classifier: Journal Article

citation:

Olomu A, Khan NNS, Todem D, Huang Q, Bottu S, Qadri S, et al. Blood pressure control in hypertensive patients in federally qualified health centers. Mdm Policy Pr. 2016;1:2381468316656010.

relatesTo

type: Cites

classifier: Journal Article

citation:

Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427–31. doi: 10.1136/bmj.326.7404.1427.

relatesTo

type: Cites

classifier: Journal Article

citation:

Bennett A, Chow CK, Chou M, Dehbi H-M, Webster R, Salam A, et al. Efficacy and safety of quarter-dose blood pressure-lowering agents: a systematic review and meta-analysis of randomized controlled trials. Hypertension. 2017;70:85–93. doi: 10.1161/HYPERTENSIONAHA.117.09202.

relatesTo

type: Cites

classifier: Journal Article

citation:

Salam A, Huffman MD, Kanukula R, Prasad EH, Sharma A, Heller DJ, et al. Two‐drug fixed‐dose combinations of blood pressure‐lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769–79. doi: 10.1111/jch.14009.

relatesTo

type: Cites

classifier: Journal Article

citation:

Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy. J Hypertens. 2019;37:1567–73. doi: 10.1097/HJH.0000000000002089.

relatesTo

type: Cites

classifier: Journal Article

citation:

Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. 2021;77:692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781.

relatesTo

type: Cites

classifier: Journal Article

citation:

Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043–52. doi: 10.1016/S0140-6736(21)01922-X.

relatesTo

type: Cites

classifier: Journal Article

citation:

Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444–452. doi: 10.1370/afm.708.

relatesTo

type: Cites

classifier: Journal Article

citation:

Baldridge AS, Huffman MD, Lazar D, Abbas H, Flowers FM, Quintana A, et al. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): rationale and design for a randomized controlled trial. Am Heart J. 2022;254:183–93. doi: 10.1016/j.ahj.2022.09.004.

relatesTo

type: Cites

classifier: Journal Article

citation:

Sanuade OA, Jacobson TA, Quintana A, Flowers FM, Abbasi H, Vu MH, et al. Process evaluation of a double blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension within a federally qualified health center network (QUARTET USA) J Am Heart Assoc. 2024;13:e032236. doi: 10.1161/JAHA.123.032236.

relatesTo

type: Cites

classifier: Journal Article

citation:

Weiss BD. Quick assessment of literacy in primary care: the Newest Vital Sign. Ann Fam Med. 2005;3:514–22. doi: 10.1370/afm.405.

relatesTo

type: Cites

citation:

Medical Dictionary for Regulatory Activities. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Available from: https://www.ich.org/page/meddra. Accessed January 9, 2024.

relatesTo

type: Cites

classifier: Journal Article

citation:

Campbell NRC, Burnens MP, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: policy implications for the region of the Americas. Lancet Regional Heal - Am. 2022;9:100219. doi: 10.1016/j.lana.2022.100219.

relatesTo

type: Cites

classifier: Journal Article

citation:

Wright JT, Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. doi: 10.1056/NEJMoa1511939.

relatesTo

type: Cites

citation:

National Association of Community Health Centers. America’s health centers fact sheet, August 2022. Available from: https://www.nachc.org/wp-content/uploads/2022/08/Americas-Health-Centers-2022_final.pdf. Accessed January 9, 2024.

relatesTo

type: Cites

classifier: Journal Article

citation:

Zheutlin AR, Caldwell D, Anstey DE, Conroy MB, Ogedegbe O, Bress AP. Trends in hypertension clinical trials focused on interventions specific for Black adults: an analysis of clinicaltrials.gov. J Am Hear Assoc. 2020;9:e018512. doi: 10.1161/JAHA.120.018512.

relatesTo

type: Cites

classifier: Journal Article

citation:

Mueller M, Purnell TS, Mensah GA, Cooper LA. Reducing racial and ethnic disparities in hypertension prevention and control: what will it take to translate research into practice and policy? Am J Hypertens. 2014;28:699–716. doi: 10.1093/ajh/hpu233.

relatesTo

type: Cites

classifier: Journal Article

citation:

Wang, Salam N, Webster A, Silva R, de A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial. JAMA Cardiol. 2020;5:1219–26. doi: 10.1001/jamacardio.2020.2739.

relatesTo

type: Cites

classifier: Journal Article

citation:

Laba T-L, Howard K, Rose J, Peiris D, Redfern J, Usherwood T, et al. Patient preferences for a polypill for the prevention of cardiovascular diseases. Ann Pharmacother. 2015;49:528–39. doi: 10.1177/1060028015570468.

relatesTo

type: Cites

classifier: Journal Article

citation:

Wood F, Salam A, Singh K, Day S, Jan S, Prabhakaran D, et al. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open. 2015;5:e008018. doi: 10.1136/bmjopen-2015-008018.

relatesTo

type: Cites

classifier: Journal Article

citation:

Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, et al. Ultra-low-dose quadruple combination blood pressure lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. Am Heart J. 2021;231:56–67. doi: 10.1016/j.ahj.2020.09.017.

relatesTo

type: Cites

classifier: Journal Article

citation:

Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389:1035–42. doi: 10.1016/S0140-6736(17)30260-X.

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1348-4214, ISOAbbreviation/Hypertens Res, ISSN Linking/0916-9636, Medline Title Abbreviation/Hypertens Res, NLM Unique ID/9307690

title: Hypertension research : official journal of the Japanese Society of Hypertension

publisherLocation: England

citedMedium: Internet

volume: 47

issue: 6

articleDate: 2024-06

publicationDateText: 2024-Jun

pageString: 1668-1677

publicationForm

citedMedium: Internet without issue

articleDate: 2024-04-08

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/38584159/

webLocation

classifier: DOI Based

url: https://doi.org/10.1038/s41440-024-01658-y

classification

type: Publishing Model

classifier: Print Electronic

classification

type: Keyword

artifactAssessment: Keywords provided by NOTNLM

classification

type: Chemical

classifier: Biphenyl Compounds, Antihypertensive Agents, Benzimidazoles, Amlodipine, Tetrazoles, candesartan, Bisoprolol, Indapamide

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Journal Article, Randomized Controlled Trial, Multicenter Study

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Huffman MD

forenameInitials: MD

affiliation:

• Cardiovascular Division and Global Health Center, Washington University in St. Louis, St. Louis, MO, USA. m.huffman@wustl.edu.
• The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. m.huffman@wustl.edu.
• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. m.huffman@wustl.edu.

entry

contributor: Baldridge AS

forenameInitials: AS

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Bluhm Cardiovascular Institute, Northwestern Medicine, Chicago, IL, USA.

entry

contributor: Lazar D

forenameInitials: D

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Abbas H

forenameInitials: H

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Mejia J

forenameInitials: J

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Flowers FM

forenameInitials: FM

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Quintana A

forenameInitials: A

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Jackson A

forenameInitials: A

affiliation: Access Community Health Network, Chicago, IL, USA.

entry

contributor: Kandula NR

forenameInitials: NR

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Division of General Internal Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Lloyd-Jones DM

forenameInitials: DM

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Persell SD

forenameInitials: SD

affiliation:

• Division of General Internal Medicine, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Center for Primary Care Innovation, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Khan SS

forenameInitials: SS

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Paparello JJ

forenameInitials: JJ

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Division of Nephrology and Hypertension, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Chopra A

forenameInitials: A

affiliation: Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Tripathi P

forenameInitials: P

affiliation: Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Vu MH

forenameInitials: MH

affiliation: Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

entry

contributor: Chow CK

forenameInitials: CK

affiliation: Westmead Applied Research Centre, University of Sydney, Westmead, NSW, Australia.

entry

contributor: Ciolino JD

forenameInitials: JD

affiliation:

• Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
• Northwestern University Data Analysis and Coordinating Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Generated Narrative: ArtifactAssessment #keywords0

artifact: Citation 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.

content

classifier: Federally qualified health centers

content

classifier: Hypertension

content

classifier: Quadpill

content

classifier: Randomized trial

content

classifier: Single pill combination

Generated Narrative: Practitioner #contributor0

name: Mark D Huffman

Generated Narrative: Practitioner #contributor1

name: Abigail S Baldridge

Generated Narrative: Practitioner #contributor2

name: Danielle Lazar

Generated Narrative: Practitioner #contributor3

name: Hiba Abbas

Generated Narrative: Practitioner #contributor4

name: Jairo Mejia

Generated Narrative: Practitioner #contributor5

name: Fallon M Flowers

Generated Narrative: Practitioner #contributor6

name: Adriana Quintana

Generated Narrative: Practitioner #contributor7

name: Alema Jackson

Generated Narrative: Practitioner #contributor8

name: Namratha R Kandula

Generated Narrative: Practitioner #contributor9

name: Donald M Lloyd-Jones

Generated Narrative: Practitioner #contributor10

name: Stephen D Persell

Generated Narrative: Practitioner #contributor11

name: Sadiya S Khan

Generated Narrative: Practitioner #contributor12

name: James J Paparello

Generated Narrative: Practitioner #contributor13

name: Aashima Chopra

Generated Narrative: Practitioner #contributor14

name: Priya Tripathi

Generated Narrative: Practitioner #contributor15

name: My H Vu

Generated Narrative: Practitioner #contributor16

name: Clara K Chow

Generated Narrative: Practitioner #contributor17

name: Jody D Ciolino

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Female

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Male

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Hypertension

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Middle Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Biphenyl Compounds

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

type: components (if present) include qualifier codings

classifier: Antihypertensive Agents

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Double-Blind Method

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Benzimidazoles

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Amlodipine

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Tetrazoles

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Blood Pressure

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: drug effects

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Aged

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Treatment Outcome

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Bisoprolol

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Indapamide

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: administration & dosage

Components

-	Type	Classifier
*	is Major topic	No

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Adult

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Drug Therapy, Combination

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic